4.6 Article

Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group

期刊

CANADIAN JOURNAL OF CARDIOLOGY
卷 27, 期 2, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cjca.2010.12.054

关键词

-

资金

  1. AstraZeneca Canada Inc
  2. Boehringer Ingelheim (Canada) Ltd
  3. Bristol-Myers Squibb Canada
  4. Eli Lilly Canada Inc
  5. GlaxoSmithKline Canada
  6. Hoffmann-La Roche Ltd
  7. Merck Frosst Canada Ltd
  8. Merck Frosst/Schering Pharmaceuticals
  9. Novartis Pharmaceuticals
  10. Novo Nordisk Canada
  11. Pfizer Canada Inc
  12. Sanofi-Aventis Canada Inc
  13. Servier Canada Inc
  14. AstraZeneca
  15. Boehringer Ingelheim
  16. Eli Lilly
  17. GlaxoSmithKline
  18. Merck
  19. Merck/Schering Plough
  20. Novartis
  21. Novo Nordisk
  22. Pfizer
  23. Roche
  24. sanofi-aventis
  25. Servier
  26. Cordis
  27. Amgen Inc
  28. Biovail
  29. Ortho-Biotech

向作者/读者索取更多资源

The concepts of cardiometabolic risk, metabolic syndrome, and risk stratification overlap and relate to the atherogenic process and development of type 2 diabetes. There is confusion about what these terms mean and how they can best be used to improve our understanding of cardiovascular disease treatment and prevention. With the objectives of clarifying these concepts and presenting practical strategies to identify and reduce cardiovascular risk in multiethnic patient populations, the Cardiometabolic Working Group reviewed the evidence related to emerging cardiovascular risk factors and Canadian guideline recommendations in order to present a detailed analysis and consolidated approach to the identification and management of cardiometabolic risk. The concepts related to cardiometabolic risk, pathophysiology, and strategies for identification and management (including health behaviours, pharmacotherapy, and surgery) in the multiethnic Canadian population are presented. Global cardiometabolic risk is proposed as an umbrella term for a comprehensive list of existing and emerging factors that predict cardiovascular disease and/or type 2 diabetes. Health behaviour interventions (weight loss, physical activity, diet, smoking cessation) in people identified at high cardiometabolic risk are of critical importance given the emerging crisis of obesity and the consequent epidemic of type 2 diabetes. Vascular protective measures (health behaviours for all patients and pharmacotherapy in appropriate patients) are essential to reduce cardiometabolic risk, and there is growing consensus that a multidisciplinary approach is needed to adequately address cardiometabolic risk factors. Health care professionals must also consider risk factors related to ethnicity in order to appropriately evaluate everyone in their diverse patient populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据